Research
Biogen Issues Community Letter with Perspective on Coronavirus (COVID-19)
Dear SMA Community, We want to provide an update on Biogen’s efforts to help ensure the health and safety of the SMA community amid the […]
Read More ›Grant Announcement: Cure SMA Awards $190,000 Grant to Umrao Monani, Ph.D., Columbia University
This article is part of a series of Cure SMA grant announcements being shared throughout the winter/spring. Cure SMA has awarded a $190,000 research grant […]
Read More ›Cure SMA Awards $100,000 Grant to Rashmi Kothary, Ph.D., Ottawa Hospital Research Institute
This article is part of a series of Cure SMA grant announcements being shared throughout the winter/spring. Cure SMA and Cure SMA Canada have awarded […]
Read More ›Grant Announcement: Cure SMA Awards $150,000 Grant to Timra Gilson, Ph.D., Indiana University
This article is part of a series of Cure SMA grant announcements being shared throughout the winter/spring. Cure SMA has awarded a $150,000 grant to […]
Read More ›Grant Announcement: Cure SMA Awards $150,000 Grant to Dmytro Morderer, Ph.D., Mayo Clinic, Jacksonville, FL
This article is part of a series of Cure SMA grant announcements that will be shared throughout the next couple of months. Cure SMA has […]
Read More ›Grant Announcement: Cure SMA Awards a $170,000 Grant to Lyndsay Murray, Ph.D., University of Edinburgh
This article is part of a series of Cure SMA grant announcements that will be shared throughout the next couple of months. Cure SMA has […]
Read More ›Cure SMA Working Group Revises Recommendations for the Treatment of Infants Diagnosed with SMA via Newborn Screening Who Have 4 Copies of SMN2
To help clinicians and the families they serve in the decision of when to administer therapy to infants identified with SMA via newborn screening, Cure […]
Read More ›Cure SMA Launches “Spotlight on SMA” Partnership with Neurology Reviews
Cure SMA is pleased to announce the release of “Spotlight on SMA: The Urgent Need for Early Diagnosis in Spinal Muscular Atrophy,” a supplement developed […]
Read More ›Genentech’s Risdiplam Showed Significant Improvement in Motor Function in People Aged 2-25 Years with Type 2 or Type 3 SMA
Genentech, a member of the Roche Group, today presented 1-year data from the pivotal Part 2 of the SUNFISH study, evaluating risdiplam in people aged […]
Read More ›Genentech’s Risdiplam Meets Primary Endpoint in Pivotal FIREFISH Trial in Infants with Type 1 SMA
Genentech, a member of the Roche Group, today announced positive topline results from the pivotal Part 2 of the FIREFISH study, evaluating risdiplam in infants […]
Read More ›